Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    September 2018
  1. SUGIMOTO K, Ikeya K, Kato M, Matsuura A, et al
    Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice.
    Dig Dis. 2018 Sep 11:1-10. doi: 10.1159/000493121.
    PubMed     Text format     Abstract available


    August 2018
  2. HOFFMANN P, Krisam J, Stremmel W, Gauss A, et al
    Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.
    Dig Dis. 2018 Aug 22:1-12. doi: 10.1159/000492322.
    PubMed     Text format     Abstract available


  3. EBRAHIMI DARYANI N, Sadr M, Soltani S, Saghazadeh A, et al
    Association of T Helper 1 Cytokine Gene Single Nucleotide Polymorphisms with Ulcerative Colitis and Crohn's Disease.
    Dig Dis. 2018 Aug 22:1-12. doi: 10.1159/000492027.
    PubMed     Text format     Abstract available


    July 2018
  4. PEYRIN-BIROULET L, Baumgart DC, Armuzzi A, Gionchetti P, et al
    Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach.
    Dig Dis. 2018 Jul 3:1-8. doi: 10.1159/000489845.
    PubMed     Text format     Abstract available


    May 2018
  5. TESTA A, Imperatore N, Rispo A, Rea M, et al
    Beyond Irritable Bowel Syndrome: The Efficacy of the Low Fodmap Diet for Improving Symptoms in Inflammatory Bowel Diseases and Celiac Disease.
    Dig Dis. 2018 May 15:1-10. doi: 10.1159/000489487.
    PubMed     Text format     Abstract available


    January 2018
  6. OHEM J, Hradsky O, Zarubova K, Copova I, et al
    Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors.
    Dig Dis. 2018;36:40-48.
    PubMed     Text format     Abstract available


  7. MOSLI M, Sabbahi H, Alyousef H, Abdulhaq M, et al
    Risk Stratification of Patients with Crohn's Disease: A Retrospective Analysis of Clinical Decision Making and Its Impact on Long-Term Outcome.
    Dig Dis. 2018;36:49-55.
    PubMed     Text format     Abstract available


  8. CUOMO A, Sgambato D, D'Auria MV, Miranda A, et al
    Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis.
    Dig Dis. 2018;36:130-135.
    PubMed     Text format     Abstract available


  9. LATERZA L, Piscaglia AC, Minordi LM, Scoleri I, et al
    Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease.
    Dig Dis. 2018;36:184-193.
    PubMed     Text format     Abstract available


  10. YOUSUF H, Aleem U, Egan R, Maheshwari P, et al
    Elevated Faecal Calprotectin Levels are a Reliable Non-Invasive Screening Tool for Small Bowel Crohn's Disease in Patients Undergoing Capsule Endoscopy.
    Dig Dis. 2018;36:202-208.
    PubMed     Text format     Abstract available


  11. GIL-BORRAS R, Garcia-Ballesteros C, Benet-Campos C, Catalan-Serra I, et al
    B1a Lymphocytes (CD19+CD5+) Deficiency in Patients with Crohn's Disease and Its Relation with Disease Severity.
    Dig Dis. 2018;36:194-201.
    PubMed     Text format     Abstract available


  12. ITO Z, Uchiyama K, Odahara S, Takami S, et al
    Fatty Acids as Useful Serological Markers for Crohn's Disease.
    Dig Dis. 2018;36:209-217.
    PubMed     Text format     Abstract available


    December 2017
  13. GREUTER T, Vavricka SR, Biedermann L, Pilz J, et al
    Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis.
    Dig Dis. 2017 Dec 5. pii: 000484979. doi: 10.1159/000484979.
    PubMed     Text format     Abstract available


    October 2017
  14. TAKEUCHI K, Shimoyama T, Yamamoto T
    Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis.
    Dig Dis. 2017 Oct 19. doi: 10.1159/000481815.
    PubMed     Text format     Abstract available


    September 2017
  15. ASL BAAKHTARI S, McCombie A, Ten Bokkel Huinink S, Irving P, et al
    Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids.
    Dig Dis. 2017 Sep 2. doi: 10.1159/000478772.
    PubMed     Text format     Abstract available


    July 2017
  16. LOPETUSO LR, Petito V, Graziani C, Schiavoni E, et al
    Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders?
    Dig Dis. 2017 Jul 7. doi: 10.1159/000477205.
    PubMed     Text format     Abstract available


    June 2017
  17. CAI JX, Barrow J, Parian A, Brant SR, et al
    Routine Pouchoscopy Prior to Ileostomy Takedown May Not Be Necessary in Patients with Chronic Ulcerative Colitis.
    Dig Dis. 2017 Jun 9. doi: 10.1159/000475808.
    PubMed     Text format     Abstract available


    April 2017
  18. PEZZILLI R, Pagano N
    Benign Exocrine Pancreatic Diseases in Inflammatory Bowel Diseases.
    Dig Dis. 2017 Apr 27. doi: 10.1159/000471481.
    PubMed     Text format     Abstract available


  19. MAHLICH J, Matsuoka K, Sruamsiri R
    Shared Decision Making and Treatment Satisfaction in Japanese Patients with Inflammatory Bowel Disease.
    Dig Dis. 2017 Apr 6. doi: 10.1159/000471795.
    PubMed     Text format     Abstract available


    March 2017
  20. ELIADOU E, Kini G, Huang J, Champion A, et al
    Intravenous Iron Replacement Improves Quality of Life in Hypoferritinemic Inflammatory Bowel Disease Patients with and without Anemia.
    Dig Dis. 2017 Mar 24. doi: 10.1159/000468145.
    PubMed     Text format     Abstract available


    January 2017
  21. PROTIC M, Markovic S, Tarabar D
    Case Report: Acute Flair of Ulcerative Colitis during Pregnancy Is Still a Major Problem.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  22. REINISCH W
    Fecal Microbiota Transplantation in Inflammatory Bowel Disease.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  23. BUER L, Hoivik ML, Medhus AW, Moum B, et al
    Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  24. COSNES J
    What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  25. DURICOVA D
    What Can We Learn from Epidemiological Studies in Inflammatory Bowel Disease?
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  26. BETTENWORTH D, Rieder F
    Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Disease and Perspectives for Therapeutic Implication.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  27. DOROFEYEV AE, Rassokhina OA, Dorofeyeva AA
    Late-Onset of Acute Severe Ulcerative Colitis: Clinical Case.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  28. KRUIS W, Nguyen PG, Morgenstern J
    Promises and Dangers of Combination Therapy.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  29. GILS A
    Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  30. HIGGINS PD
    Measurement of Fibrosis in Crohn's Disease Strictures with Imaging and Blood Biomarkers to Inform Clinical Decisions.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  31. STANGE EF
    Improvement of a 'Leaky' Intestinal Barrier.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  32. ROGLER G, Biedermann L, Scharl M
    Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-alpha Therapy: Pathophysiology and Clinical Implications.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  33. SANDS BE
    Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  34. JAHNSEN J, Kaasen Jorgensen K
    Experience with Biosimilar Infliximab (Remsima(R)) in Norway.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  35. DRASTICH P, Oliverius M
    Crohn's Disease and Intestinal Transplantation.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  36. VEGH Z, Kurti Z, Lakatos PL
    Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  37. FORBES GM
    Mesenchymal Stromal Cell Therapy in Crohn's Disease.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  38. KVERKA M, Tlaskalova-Hogenova H
    Intestinal Microbiota: Facts and Fiction.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  39. HAWKEY CJ
    Hematopoietic Stem Cell Transplantation in Crohn's Disease: State-of-the-Art Treatment.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  40. KOLAR M, Duricova D, Bortlik M, Hruba V, et al
    Infliximab Biosimilar (Remsima) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  41. VAVRICKA SR, Spasojevic M, Rogler G, Schoepfer AM, et al
    Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
    Dig Dis. 2017;35:423-432.
    PubMed     Text format     Abstract available


  42. ZHENG S, Wu C, Yang W, Xia X, et al
    An Analysis of Transcobalamin II Gene Polymorphisms and Serum Levels of Homocysteine, Folate and Vitamin B12 in Chinese Patients with Crohn's Disease.
    Dig Dis. 2017;35:463-471.
    PubMed     Text format     Abstract available


    January 2016
  43. MANTZARIS GJ
    Anti-TNFs: Originators and Biosimilars.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  44. BERNSTEIN CN
    Psychological Stress and Depression: Risk Factors for IBD?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  45. DANESE S, Fiocchi C
    Endothelial Cell-Immune Cell Interaction in IBD.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  46. FEDORAK RN, Ismond KP
    Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  47. LEONG RW, Mitrev N, Ko Y
    Hygiene Hypothesis: Is the Evidence the Same All Over the World?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  48. KRUIS W, Phuong Nguyen G
    Iron Deficiency, Zinc, Magnesium, Vitamin Deficiencies in Crohn's Disease: Substitute or Not?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  49. MAO R, Hu PJ
    The Future of IBD Therapy: Where Are We and Where Should We Go Next?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  50. WRIGHT EK
    Calprotectin or Lactoferrin: Do They Help.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  51. BLUMBERG RS
    Environment and Genes: What Is the Interaction?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  52. YANG SK
    Personalizing IBD Therapy: The Asian Perspective.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  53. CHO JH
    The Promise of Epigenetics. Has It Delivered New Insights?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  54. IACUCCI M, Ghosh S
    Mucosal Healing - How Deep Is Enough?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  55. GEARRY RB
    IBD and Environment: Are There Differences between East and West.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  56. VAVRICKA SR, Rogler G, Biedermann L
    High Altitude Journeys, Flights and Hypoxia: Any Role for Disease Flares in IBD Patients?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  57. KURTI Z, Vegh Z, Golovics PA, Lakatos PL, et al
    'Treat to Target' - Lessons Learnt.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  58. ROGLER G
    Preface.
    Dig Dis. 2016;34.
    PubMed     Text format    


  59. COSNES J
    Smoking and Diet: Impact on Disease Course?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  60. HERFARTH HH
    Methotrexate for Inflammatory Bowel Diseases - New Developments.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  61. KUMP P, Hogenauer C
    Any Future for Fecal Microbiota Transplantation as Treatment Strategy for Inflammatory Bowel Diseases?
    Dig Dis. 2016;34 Suppl 1:74-81.
    PubMed     Text format     Abstract available


  62. KHANNA R, Feagan BG
    Emerging Therapies for Inflammatory Bowel Diseases.
    Dig Dis. 2016;34 Suppl 1:67-73.
    PubMed     Text format     Abstract available


  63. LISSNER D, Siegmund B
    Are Immunosuppressants Becoming Obsolete?
    Dig Dis. 2016;34 Suppl 1:56-60.
    PubMed     Text format     Abstract available


  64. HILDNER K, Punkenburg E, Abendroth B, Neurath MF, et al
    Immunopathogenesis of IBD: Batf as a Key Driver of Disease Activity.
    Dig Dis. 2016;34 Suppl 1:40-7.
    PubMed     Text format     Abstract available


  65. ATREYA R, Neurath MF
    Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases.
    Dig Dis. 2016;34:552-7.
    PubMed     Text format     Abstract available


  66. XAVIER RJ
    Microbiota as Therapeutic Targets.
    Dig Dis. 2016;34:558-65.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: